Bifogade filer
PDF
Kurs
+3,70%
Likviditet
0,03 MSEK
Kalender
| Tid* | ||
| 2025-08-29 | 10:00 | Bokslutskommuniké 2025 |
| 2025-05-09 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-02-07 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2024-11-04 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2024-11-01 | - | Årsstämma |
| 2024-10-28 | - | Kvartalsrapport 2025-Q1 |
| 2024-08-30 | - | Bokslutskommuniké 2024 |
| 2024-04-19 | - | Kvartalsrapport 2024-Q3 |
| 2024-04-12 | - | Extra Bolagsstämma 2024 |
| 2024-02-09 | - | Kvartalsrapport 2024-Q2 |
| 2023-10-27 | - | Kvartalsrapport 2024-Q1 |
| 2023-09-25 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2023-09-22 | - | Årsstämma |
| 2023-08-31 | - | Bokslutskommuniké 2023 |
| 2023-05-04 | - | Kvartalsrapport 2023-Q3 |
| 2023-02-09 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-27 | - | Kvartalsrapport 2023-Q1 |
| 2022-10-07 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2022-10-06 | - | Årsstämma |
| 2022-08-30 | - | Bokslutskommuniké 2022 |
| 2022-07-05 | - | Extra Bolagsstämma 2022 |
| 2022-05-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-02-11 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-22 | - | Kvartalsrapport 2022-Q1 |
| 2021-10-06 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2021-10-05 | - | Årsstämma |
| 2021-08-30 | - | Bokslutskommuniké 2021 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-02-12 | - | Kvartalsrapport 2021-Q2 |
| 2020-11-12 | - | Kvartalsrapport 2021-Q1 |
| 2020-10-08 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2020-10-07 | - | Årsstämma |
| 2020-08-31 | - | Bokslutskommuniké 2020 |
| 2020-05-15 | - | Kvartalsrapport 2020-Q3 |
| 2020-05-04 | - | Extra Bolagsstämma 2020 |
| 2020-02-14 | - | Kvartalsrapport 2020-Q2 |
| 2019-11-01 | - | Kvartalsrapport 2020-Q1 |
| 2019-10-10 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2019-10-09 | - | Årsstämma |
| 2019-08-30 | - | Bokslutskommuniké 2019 |
| 2019-05-16 | - | Kvartalsrapport 2019-Q3 |
| 2019-02-14 | - | Kvartalsrapport 2019-Q2 |
| 2018-10-30 | - | Kvartalsrapport 2019-Q1 |
| 2018-10-17 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2018-10-16 | - | Årsstämma |
| 2018-08-31 | - | Bokslutskommuniké 2018 |
| 2018-05-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-02-14 | - | Kvartalsrapport 2018-Q2 |
| 2017-10-30 | - | Kvartalsrapport 2018-Q1 |
| 2017-10-02 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2017-09-29 | - | Årsstämma |
| 2017-08-30 | - | Bokslutskommuniké 2017 |
| 2017-05-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-02-20 | - | Kvartalsrapport 2017-Q2 |
| 2017-01-25 | - | Extra Bolagsstämma 2017 |
| 2016-11-07 | - | Kvartalsrapport 2017-Q1 |
| 2016-08-29 | - | X-dag ordinarie utdelning VSD B 0.00 SEK |
| 2016-08-26 | - | Bokslutskommuniké 2016 |
| 2016-05-26 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-25 | - | Kvartalsrapport 2016-Q2 |
| 2015-11-26 | - | Kvartalsrapport 2016-Q1 |
| 2015-08-27 | - | Bokslutskommuniké 2015 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
VibroSense Dynamics AB has signed an agreement with LifeMed OY in Finland. The agreement allows LifeMed OY to market and sell VibroSense Meter II in Finland within the product's application areas.
"We are excited to have started this cooperation with LifeMed in the Finnish market. VibroSense Meter II has a wide range of applications and we look forward to offering our solutions in Finland together with LifeMed", says Tarik Cengiz, CEO of VibroSense Dynamics AB.
Contact
Tarik Cengiz, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
E-mail: info@vibrosense.com
www.vibrosense.com
"The new Gold Standard for reliable
detection of nerve damage"
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products to facilitate diagnosis of peripheral nerve damage in the hands and feet. The method involves measuring and quantifying the ability to perceive vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, point of care centers and researchers.
Our vision is for the company's products to be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.